Design and Analysis Considerations for Safety Data, Particularly Adverse Events

Karl E. Peace

Design and Analysis Considerations for Safety Data, Particularly Adverse Events

Karl E. Peace

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to book or proceeding › Chapter

Abstract

Prior to employment at Georgia Southern University, Karl E. Peace authored "Design and Analysis Considerations for Safety Data, Particularly Adverse Events" in Drug Safety Assessment in Clinical Trials.

Original language	American English
Title of host publication	Drug Safety Assessment in Clinical Trials
State	Published - Jul 14 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Biostatistics
Public Health

Keywords

Adverse events
Analysis
Considerations
Design
Safety data

Cite this

@inbook{d713412d1a4d4c5d8f280d8115a9d506,

title = "Design and Analysis Considerations for Safety Data, Particularly Adverse Events",

abstract = " Prior to employment at Georgia Southern University, Karl E. Peace authored {"}Design and Analysis Considerations for Safety Data, Particularly Adverse Events{"} in Drug Safety Assessment in Clinical Trials. ",

keywords = "Adverse events, Analysis, Considerations, Design, Safety data",

author = "Peace, \{Karl E.\}",

note = "Details the methods pharmaceutical companies employ to determine the safety profile of their drugs. Statistical procedures currently used or developed to analyze, display and compare the massive amounts of laboratory data collected from controlled clinical trials are surveyed.",

year = "1993",

month = jul,

day = "14",

language = "American English",

booktitle = "Drug Safety Assessment in Clinical Trials",

}

TY - CHAP

T1 - Design and Analysis Considerations for Safety Data, Particularly Adverse Events

AU - Peace, Karl E.

N1 - Details the methods pharmaceutical companies employ to determine the safety profile of their drugs. Statistical procedures currently used or developed to analyze, display and compare the massive amounts of laboratory data collected from controlled clinical trials are surveyed.

PY - 1993/7/14

Y1 - 1993/7/14

N2 - Prior to employment at Georgia Southern University, Karl E. Peace authored "Design and Analysis Considerations for Safety Data, Particularly Adverse Events" in Drug Safety Assessment in Clinical Trials.

AB - Prior to employment at Georgia Southern University, Karl E. Peace authored "Design and Analysis Considerations for Safety Data, Particularly Adverse Events" in Drug Safety Assessment in Clinical Trials.

KW - Adverse events

KW - Analysis

KW - Considerations

KW - Design

KW - Safety data

UR - https://www.amazon.com/Safety-Assessment-Clinical-Trials-Statistics/dp/0824788931/

M3 - Chapter

BT - Drug Safety Assessment in Clinical Trials

ER -

Design and Analysis Considerations for Safety Data, Particularly Adverse Events

Abstract

UN SDGs

Disciplines

Keywords

Other files and links

Fingerprint

Cite this